Non-clinical safety studies for biotechnologically-derived pharmaceuticals: Conclusions from an international workshop

Human and Experimental Toxicology

Volumn 17, Issue 2, 1998, Pages 63-83

  Griffiths, Susan A ^a   Lumley, Cyndy E ^a  

^a Ctr for Medicines Res Intl   (United Kingdom)

Author keywords

Biotechnology; Non clinical; Pharmaceutical; Safety evaluation

Indexed keywords

COLONY STIMULATING FACTOR; GROWTH FACTOR; HORMONE; INTERFERON; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY;

BIOTECHNOLOGY; CARCINOGENICITY; GENE THERAPY; GENOTOXICITY; PRIORITY JOURNAL; REVIEW; SAFETY; TOXICITY TESTING;

ANIMALS; BIOTECHNOLOGY; DRUG DESIGN; DRUG TOXICITY; HUMANS; RECOMBINANT PROTEINS;

EID: 0031907908     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032798678908341     Document Type: Review

References (22)

1. Non-clinical Safety Testing of Products of Biotechnology: Issues of Concern. Griffiths SA, Ashton GA and Lumley CE. CMR International Report, CMR95-63R, December 1995.
2. Safety Evaluation of Biotechnologically-derived pharmaceuticals: Facilitating a Scientific Approach, (eds) Griffiths SA and Lumley CE. Kluwer Academic Publishers: The Netherlands, 1997. ISBN 0-7923-8732-5.
3. Mannering GJ, DeLoria LB. The pharmacology and toxicology of the interferons; an overview. Annual Review of Pharmacology and Toxicology 1986; 26: 455-515.
4. Hayes TJ, Cavagnaro JA. Progress and challenges in the preclinical assessment of cytokines. Toxicology Letters 1992; 64/65: 291-297.
5. Siegel JP et al Development of biological therapies for oncologic use. In: Biologic Therapy of Cancer 1995; 2nd ed (eds) DeVita VT. Hellman S and Rosenberg SA, JB Lippincott Company, pp 879-890.
6. Ryffel B. Cytokine induced pathology. International Review of Experimental Pathology 1993; 34 A and B.
7. Sreevalasan T. Biologic therapy with interferon-alpha and beta: preclinical studies. In: Biologic Therapy of Cancer. 1995; 2nd ed, (eds) Devita VT, Hellman S and Rosenberg SA, JB Lippincott Company, pp 347-364.
8. Tushinski RJ, Mule JJ. Biology of cytokines: the interleukins. In: Biologic Therapy of Cancer. 1995; 2nd ed, (eds) DeVita VT, Hellman S and Rosenberg SA, JB Lippincott Company, pp 87-102.
9. Hayes TJ, Ryffel B. Safety considerations for recombinant protein therapy: introductory comments. Clinical Immunology and Immunopathology 1997; 83: 1-4.
10. Anderson TD, Arceco R, Hayes TJ. Comparative toxicity and pathology associated with administration of recombinant HuIL-1 alpha to animals. International Review of Experimental Pathology 1993; 34(A): 9-36.
11. Anderson TD et al. Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. International Review of Experimental Pathology 1993; 34A: 57-77.
12. Renton KW, Mannering GJ. Depression of hepatic cytochrome P-450 dependent monooxygenase systems with administered interferon inducing agents. Biochemical and Biophysical Research Communications 1976; 73: 343-348.
13. Parkinson A et al. Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metabolism and Disposition 1982; 10 579-585.
14. Renton KW, Knuckle LC. Regulation of hepatic cytochrome P-450 during infectious disease. Canadian Journal of Physiology and Pharmacology 1990; 68: 777-781.
15. Cribb AE et al. Regulation of cytochrome P-450A and cytochrome P-4502E induction in the rat during the production of interferon alpha/beta. Journal of Pharmacology and Experimental Therapeutics 1994; 268: 487-494.
16. Anari MR, Cribb AE, Renton KW. The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid-polycytidylic acid. Drug Metabolism and Disposition 1995; 23: 536-541.
17. Trown PW, Wills RJ, Kamm JJ. The preclinical development of Roferon-A. Cancer 1986; 57: 1648-1656.
18. Terrel J, Green JD. Comparative pathology of recombinant murine interferon-gamma in mice and recombinant human interferon-gamma in cynomologous monkeys. International Review of Experimental Pathology 1993; 34B: 73-101.
19. Ryffel B. Interleukin-12: role of interferon-gamma in IL-12 adverse effects. Clinical Immunology and Immunopathology 1997; 83: 18-20.
20. Hall SS. IL-12 at the crossroads [news]. Science 1995; 268: 1432-1434.
21. Lotze M, Gately M. Interleukin-12. Annals of the New York Academy of Sciences. 1996.
22. Lipani J. Designing non-clinical safety evaluation programmes: The view of the clinician. In: Safety Evaluation of Biotechnologically-derived pharmaceuticals: Facilitating a Scientific Approach. (Eds) Griffiths SA and Lumley CE. Kluwer Academic Publishers: The Netherlands. 1997. ISBN 0-7923-8732-5.